Tilmovet AC is also for the control of swine respiratory disease associated with Mycoplasma hyopneumoniae in the presence of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) in groups of swine in buildings where a respiratory disease outbreak is diagnosed. Comprised of the active ingredient tilmicosin phosphate, Tilmovet AC is a bio-equivalent product to Pulmotil® AC.
“We are thrilled to continue our commitment to building a broad portfolio for the swine industry with the recent approval of our Tilmovet AC. This addition is complementary to our current product offering, but will also play an important role as we look to future growth of Huvepharma’s swine portfolio,” says Drew Weir, Director of Huvepharma’s Integrator Business Unit.
Tilmovet AC is the first generic aqueous concentrate approved by the FDA that controls swine respiratory disease associated with Mycoplasma hyopneumoniae in the presence of PRRSV in groups of swine in buildings where a respiratory disease outbreak is diagnosed. This approval further demonstrates Huvepharma’s commitment to providing producers with quality and effective choices.
Dr. David Nolan, Sr. veterinarian on Huvepharma’s swine team, sums up our excitement with these words; “It is with great excitement that the Huvepharma swine team is bringing Tilmovet AC to the US pig industry. This new choice represents Huvepharma’s ongoing commitment to bringing solutions to the veterinarians and producers we serve. Our Tilmovet AC product will be a welcome addition to the ongoing battle against swine respiratory disease. When you have choices, you have control!”
Throughout the US, Huvepharma is focused on building partnerships with industry customers by offering high quality products and unparalleled customer service. For more information, please contact your Huvepharma sales representative and/or Huvepharma’s Customer Service team at +1-887-994-4883 or visit www.huvepharma.us.
